Literature DB >> 26573560

FAM172A protein promotes the proliferation of human papillary thyroid carcinoma cells via the p38 mitogen-activated protein kinase pathway.

Mei-Fang Li1, Rong Zhang1, Ming-Gao Guo2, Lian-Xi Li1, Han-Kui Lu3, Jun-Xi Lu1, Wei-Ping Jia1.   

Abstract

Family with sequence similarity 172, member A (FAM172A), was cloned from human aortic tissues and confirmed in our previous study in 2009, however, its functions remain to be fully elucidated. In our previous studies, the protein expression of FAM172A in human aortic smooth muscle cells was found to be upregulated by high glucose in a concentration‑ and time‑dependent manner. Several reports have shown that insulin resistance is associated with papillary thyroid carcinoma (PTC). Thus, in the present study, the protein expression levels of FAM172A in human papillary thyroid carcinoma were investigated, and the effect of the FAM172A protein on the proliferation of IHH‑4 human papillary thyroid carcinoma cells, and its potential molecular underlying mechanisms were examined. Immunohistochemistry and western blotting demonstrated that the protein expression of FAM172A in papillary thyroid carcinoma tissues was not only significantly higher than that in noncancerous tissues adjacent to the carcinoma tissues, but it was also markedly higher than that in normal thyroid and thyroid adenoma tissues. Overexpression of the FAM172A protein activated the p38 MAPK pathway, but not the PI3K and AMPK pathways, in the IHH‑4 cells. In addition, overexpression of the FAM172A protein accelerated IHH‑4 cell proliferation, compared with the control group, and the pro‑proliferative effect of FAM172A protein on IHH4 cells was markedly attenuated by SB202190, an inhibitor of p38 MAPK. Taken together, these results suggest that the FAM172A protein is expressed at high levels in human PTC, which may promote cell proliferation via activation of the p38 MAPK signaling pathway, and be involved in the pathogenesis of PTC.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26573560     DOI: 10.3892/mmr.2015.4548

Source DB:  PubMed          Journal:  Mol Med Rep        ISSN: 1791-2997            Impact factor:   2.952


  6 in total

1.  Identification of Differentially Expressed Kinase and Screening Potential Anticancer Drugs in Papillary Thyroid Carcinoma.

Authors:  Huairong Zhang; Bo Gao; Bingyin Shi
Journal:  Dis Markers       Date:  2016-09-15       Impact factor: 3.434

2.  FAM172A expression in circulating tumor cells for prediction of high-risk subgroups of colorectal cancer.

Authors:  Chang Xu; Chunhong Zhang; Haowen Wang; Han Yang; Gang Li; Zhenghua Fei; Wenfeng Li
Journal:  Onco Targets Ther       Date:  2017-03-30       Impact factor: 4.147

3.  FAM172A inhibits EMT in pancreatic cancer via ERK-MAPK signaling.

Authors:  Ying Chen; Peihui Liu; Di Shen; Han Liu; Lepeng Xu; Jian Wang; Daguang Shen; He Sun; Hongkui Wu
Journal:  Biol Open       Date:  2020-02-07       Impact factor: 2.422

4.  The Effect of Protein FAM172A on Proliferation in HepG2 Cells and Investigation of the Possible Molecular Mechanism.

Authors:  Hong Zhao; Yujie Wang; Yufeng Liu; Xiaohua Hao; Hongshan Wei; Wen Xie
Journal:  Anal Cell Pathol (Amst)       Date:  2019-12-13       Impact factor: 2.916

5.  FAM172A promotes follicular thyroid carcinogenesis and may be a marker of FTC.

Authors:  Pei-Pei Xu; Su Zeng; Xiao-Tian Xia; Zi-Heng Ye; Mei-Fang Li; Ming-Yun Chen; Tian Xia; Jing-Jing Xu; Qiong Jiao; Liang Liu; Lian-Xi Li; Ming-Gao Guo
Journal:  Endocr Relat Cancer       Date:  2020-11       Impact factor: 5.678

6.  FAM172A affects cell proliferation and apoptosis not by targeting β-tubulin in HepG2 cells.

Authors:  Ai-Min Xu; Chuan-Jiang He; Zureguli Tuerxun; Abuduaini Anikezi
Journal:  Transl Cancer Res       Date:  2020-09       Impact factor: 1.241

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.